183 related articles for article (PubMed ID: 19050307)
21. Formation of immunoglobulin light chain amyloid oligomers in primary cutaneous nodular amyloidosis.
Clos AL; Lasagna-Reeves CA; Castillo-Carranza DL; Sengupta U; Jackson GR; Kelly B; Beachkofsky TM; Kayed R
Br J Dermatol; 2011 Dec; 165(6):1349-54. PubMed ID: 21729025
[TBL] [Abstract][Full Text] [Related]
22. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.
Palladini G; Russo P; Bosoni T; Verga L; Sarais G; Lavatelli F; Nuvolone M; Obici L; Casarini S; Donadei S; Albertini R; Righetti G; Marini M; Graziani MS; Melzi D'Eril GV; Moratti R; Merlini G
Clin Chem; 2009 Mar; 55(3):499-504. PubMed ID: 19131635
[TBL] [Abstract][Full Text] [Related]
23. A patient with AL amyloidosis with negative free light chain results.
Milani P; Valentini V; Ferraro G; Basset M; Russo F; Foli A; Palladini G; Merlini G
Clin Chem Lab Med; 2016 Jun; 54(6):1035-7. PubMed ID: 26677890
[TBL] [Abstract][Full Text] [Related]
24. Light chain amyloidosis: Where are the light chains from and how they play their pathogenic role?
Zhang C; Huang X; Li J
Blood Rev; 2017 Jul; 31(4):261-270. PubMed ID: 28336182
[TBL] [Abstract][Full Text] [Related]
25. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity.
Oliva L; Orfanelli U; Resnati M; Raimondi A; Orsi A; Milan E; Palladini G; Milani P; Cerruti F; Cascio P; Casarini S; Rognoni P; Touvier T; Marcatti M; Ciceri F; Mangiacavalli S; Corso A; Merlini G; Cenci S
Blood; 2017 Apr; 129(15):2132-2142. PubMed ID: 28130214
[TBL] [Abstract][Full Text] [Related]
26. Immunoglobulin light chain amyloid aggregation.
Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis.
Buxbaum JN; Chuba JV; Hellman GC; Solomon A; Gallo GR
Ann Intern Med; 1990 Mar; 112(6):455-64. PubMed ID: 2106817
[TBL] [Abstract][Full Text] [Related]
28. Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis.
Perfetti V; Ubbiali P; Magni M; Colli Vignarelli M; Casarini S; Matteucci P; Gianni AM; Merlini G
Bone Marrow Transplant; 1999 Feb; 23(4):323-7. PubMed ID: 10100575
[TBL] [Abstract][Full Text] [Related]
29. New developments in diagnosis, risk assessment and management in systemic amyloidosis.
Vaxman I; Dispenzieri A; Muchtar E; Gertz M
Blood Rev; 2020 Mar; 40():100636. PubMed ID: 31706583
[TBL] [Abstract][Full Text] [Related]
30. A reappraisal of immunoglobulin variable gene primers and its impact on assessing clonal relationships between PB B cells and BM plasma cells in AL amyloidosis.
Katoh N; Poshusta TL; Manske MK; Dispenzieri A; Gertz MA; Abraham RS; Ramirez-Alvarado M
J Clin Immunol; 2011 Dec; 31(6):1029-37. PubMed ID: 21909811
[TBL] [Abstract][Full Text] [Related]
31. Nodular pulmonary immunoglobulin light chain deposits with coexistent amyloid and nonamyloid features in an HIV-infected patient.
Stokes MB; Jagirdar J; Burchstin O; Kornacki S; Kumar A; Gallo G
Mod Pathol; 1997 Oct; 10(10):1059-65. PubMed ID: 9346188
[TBL] [Abstract][Full Text] [Related]
32. Antibodies gone bad - the molecular mechanism of light chain amyloidosis.
Absmeier RM; Rottenaicher GJ; Svilenov HL; Kazman P; Buchner J
FEBS J; 2023 Mar; 290(6):1398-1419. PubMed ID: 35122394
[TBL] [Abstract][Full Text] [Related]
33. A case of nodular cutaneous amyloidosis. Amyloid production by infiltrating plasma cells.
Horiguchi Y; Takahashi C; Imamura S
Am J Dermatopathol; 1993 Feb; 15(1):59-63. PubMed ID: 8434733
[TBL] [Abstract][Full Text] [Related]
34. Use of novel therapies in the treatment of light chain amyloidosis.
Varga C; Titus SE; Toskic D; Comenzo RL
Blood Rev; 2019 Sep; 37():100581. PubMed ID: 31167719
[TBL] [Abstract][Full Text] [Related]
35. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis
Renz M; Torres R; Dolan PJ; Tam SJ; Tapia JR; Li L; Salmans JR; Barbour RM; Shughrue PJ; Nijjar T; Schenk D; Kinney GG; Zago W
Amyloid; 2016 Sep; 23(3):168-177. PubMed ID: 27494229
[TBL] [Abstract][Full Text] [Related]
36. Amyloid neuropathy: immunocytochemical localization of intra- and extracellular immunoglobulin light chains.
Sommer C; Schröder JM
Acta Neuropathol; 1989; 79(2):190-9. PubMed ID: 2512758
[TBL] [Abstract][Full Text] [Related]
37. Diagnosis and management of systemic light chain AL amyloidosis.
Bhutani D; Lentzsch S
Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
[TBL] [Abstract][Full Text] [Related]
38. Abnormal immunoglobulin synthesis in monoclonal immunoglobulin light chain and light and heavy chain deposition disease.
Buxbaum JN
Amyloid; 2001 Jun; 8(2):84-93. PubMed ID: 11409038
[TBL] [Abstract][Full Text] [Related]
39. The Process of Amyloid Formation due to Monoclonal Immunoglobulins.
Morgan GJ; Wall JS
Hematol Oncol Clin North Am; 2020 Dec; 34(6):1041-1054. PubMed ID: 33099422
[TBL] [Abstract][Full Text] [Related]
40. Structural analysis of the amyloidogenic kappa Bence Jones protein (FUR).
Odani S; Komori Y; Gejyo F
Amyloid; 1999 Jun; 6(2):77-88. PubMed ID: 10439113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
